Compare Ascendis Pharma A/S (ASND) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs JetBlue Airways Corporation — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while JetBlue Airways Corporation trades at $5.69 (market cap $2.14B). The key difference: Ascendis Pharma A/S is far larger — about 8.3× JetBlue Airways Corporation's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | JBLU | |
|---|---|---|
Market Cap | $17.74B | $2.14B |
Sector | Health | Industrials |
52-Week High | $277.18 | $6.46 |
52-Week Low | $163.32 | $4.03 |
Enterprise Value | $18.11B | $9.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
JetBlue (JBLU) trades at $5.76, down 2.7% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported a net loss of $602 million in 2025, with negative profit margins and elevated debt levels. Recent news highlights a major Fort Lauderdale expansion, while analyst consensus is predominantly Hold with a $5.12 price target below the current price.
The outlook remains challenging due to persistent losses and high leverage, though expansion efforts and potential fuel cost relief offer some upside. Key risks include volatile oil prices, competitive pressure, and execution of the turnaround strategy. Investors should weigh cost management improvements against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
